Suspends limitations on conference committee jurisdiction for Senate Bill 2308.

Suspends limitations on conference committee jurisdiction to allow changes to Senate Bill 2308, which involves the establishment of a consortium to conduct drug development clinical trials with ibogaine. The bill includes provisions for consortium formation, proposal requirements, funding, and reporting. It also defines terms such as "comptroller," "drug developer," "hospital," and "institution of higher education." The bill aims to secure FDA approval for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions.

Suspends limitations on conference committee jurisdiction for Senate Bill 2308.

Suspends limitations on conference committee jurisdiction to allow changes to Senate Bill 2308, which involves the establishment of a consortium to conduct drug development clinical trials with ibogaine. The bill includes provisions for consortium formation, proposal requirements, funding, and reporting. It also defines terms such as "comptroller," "drug developer," "hospital," and "institution of higher education." The bill aims to secure FDA approval for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions.